Serological surveillance of influenza in an English sentinel network: pilot study protocol.
data collection
influenza, human
medical records systems, computerized
pandemics
population surveillance
primary health care
records as topic
seroepidemiologic studies
serology
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
08 03 2019
08 03 2019
Historique:
entrez:
11
3
2019
pubmed:
11
3
2019
medline:
31
3
2020
Statut:
epublish
Résumé
Rapidly undertaken age-stratified serology studies can produce valuable data about a new emerging infection including background population immunity and seroincidence during an influenza pandemic. Traditionally seroepidemiology studies have used surplus laboratory sera with little or no clinical information or have been expensive detailed population based studies. We propose collecting population based sera from the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), a sentinel network with extensive clinical data. To pilot a mechanism to undertake population based surveys that collect serological specimens and associated patient data to measure seropositivity and seroincidence due to seasonal influenza, and create a population based serology bank. METHODS AND ANALYSIS: We will send the samples to the Public Health England (PHE) Seroepidemiology Unit for processing and storage. These samples will be tested for influenza antibodies, using haemagglutination inhibition assays. Serology results will be pseudonymised, sent to the RCGP RSC and combined using existing processes at the RCGP RSC secure hub. The influenza seroprevalence results from the RCGP cohort will be compared against those from the annual PHE influenza residual serosurvey. Ethical approval was granted by the Proportionate Review Sub- Committee of the London - Camden & Kings Cross on 6 February 2018. This study received approval from Health Research Authority on 7 February 2018. On completion the results will be made available via peer-reviewed journals.
Sections du résumé
BACKGROUND
Rapidly undertaken age-stratified serology studies can produce valuable data about a new emerging infection including background population immunity and seroincidence during an influenza pandemic. Traditionally seroepidemiology studies have used surplus laboratory sera with little or no clinical information or have been expensive detailed population based studies. We propose collecting population based sera from the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), a sentinel network with extensive clinical data.
AIM
To pilot a mechanism to undertake population based surveys that collect serological specimens and associated patient data to measure seropositivity and seroincidence due to seasonal influenza, and create a population based serology bank. METHODS AND ANALYSIS:
METHODS
We will send the samples to the Public Health England (PHE) Seroepidemiology Unit for processing and storage. These samples will be tested for influenza antibodies, using haemagglutination inhibition assays. Serology results will be pseudonymised, sent to the RCGP RSC and combined using existing processes at the RCGP RSC secure hub. The influenza seroprevalence results from the RCGP cohort will be compared against those from the annual PHE influenza residual serosurvey.
ETHICS AND DISSEMINATION
Ethical approval was granted by the Proportionate Review Sub- Committee of the London - Camden & Kings Cross on 6 February 2018. This study received approval from Health Research Authority on 7 February 2018. On completion the results will be made available via peer-reviewed journals.
Identifiants
pubmed: 30852535
pii: bmjopen-2018-024285
doi: 10.1136/bmjopen-2018-024285
pmc: PMC6429844
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e024285Informations de copyright
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: Simon de Lusignan has received grant funding through University of Surrey from GSK to report vaccine adverse events and attended advisory boards for Sanofi and Seqirus.
Références
N Engl J Med. 2014 Apr 3;370(14):1335-42
pubmed: 24693893
Vaccine. 2018 May 17;36(21):3034-3040
pubmed: 29680198
Inform Prim Care. 2014;21(2):61-3
pubmed: 24841404
BMJ Open. 2016 Apr 20;6(4):e011092
pubmed: 27098827
Clin Infect Dis. 2014 Jan;58(2):181-7
pubmed: 24149079
Br J Gen Pract. 2015 Feb;65(631):54-5
pubmed: 25624277
Stud Health Technol Inform. 2018;247:161-165
pubmed: 29677943
Lancet. 2017 Jan 21;389(10066):252
pubmed: 28118913
Br J Gen Pract. 2017 Jan;67(654):e29-e40
pubmed: 27993900
Influenza Other Respir Viruses. 2013 Mar;7(2):211-24
pubmed: 22548725
Emerg Infect Dis. 2012 Nov;18(11):1894-7
pubmed: 23092684
Clin Vaccine Immunol. 2014 Aug;21(8):1054-60
pubmed: 24872516
BMJ. 2017 Nov 9;359:j5084
pubmed: 29122753
Inform Prim Care. 2005;13(1):65-70
pubmed: 15949178
Stud Health Technol Inform. 2008;141:111-8
pubmed: 18953131
Euro Surveill. 2016 Sep 22;21(38):
pubmed: 27684603
Br J Gen Pract. 2017 Oct;67(663):440-441
pubmed: 28963401
Eur J Hum Genet. 2015 Jun;23(6):721-8
pubmed: 25248399
Paediatr Drugs. 2016 Aug;18(4):303-18
pubmed: 27272706
Lancet. 2017 Jan 21;389(10066):250-251
pubmed: 28118910
Lancet. 2016 Aug 13;388(10045):728-30
pubmed: 27059886
Inform Prim Care. 2006;14(3):203-9
pubmed: 17288707
Euro Surveill. 2015;20(39):
pubmed: 26537222